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Abstract
Background: T-helper (Th) 22 is involved in the pathogenesis of inflammatory diseases. The roles of Th22 cells in the
pathophysiological of ankylosing spondylitis (AS) and rheumatoid arthritis (RA) remain unsettled. So we examined the
frequencies of Th22 cells, Th17 cells and Th1 cells in peripheral blood (PB) from patients with AS and patients with RA
compared with both healthy controls as well as patients with osteoarthritis.
Design and Methods: We studied 32 AS patients, 20 RA patients, 10 OA patients and 20 healthy controls. The expression of
IL-22, IL-17 and IFN-c were examined in AS, RA, OA patients and healthy controls by flow cytometry. Plasma IL-22 and IL-17
levels were examined by enzyme-linked immunosorbent assay.
Results: Th22 cells, Th17 cells and interleukin-22 were significantly elevated in AS and RA patients compared with OA
patients and healthy controls. Moreover, Th22 cells showed positive correlation with Th17 cells as well as interleukin-22 in
AS and RA patients. However, positive correlation between IL-22 and Th17 cells was only found in AS patients not in RA
patients. In addition, the percentages of both Th22 cells and Th17 cells correlated positively with disease activity only in RA
patients not in AS patients.
Conclusions: The frequencies of both Th22 cells and Th17 cells were elevated in PB from patients with AS and patients with
RA. These findings suggest that Th22 cells and Th17 cells may be implicated in the pathogenesis of AS and RA, and Th22
cells and Th17 cells may be reasonable cellular targets for therapeutic intervention.
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Introduction
Ankylosing spondylitis (AS) is a chronic inammatory disease that
is characterized by mainly involving bilateral sacroiliitis and axial
joints, but sometimes peripheral joints and extra-articular organs
are also involved [1]. Rheumatoid arthritis (RA), which represents
an example of autoimmunity disease, is another form of arthritis.
The abnormality of T cells is implicated in the pathogenesis of
many autoimmune diseases, and many autoimmune diseases,
especially arthritis, were considered to be mainly driven by Th1
cells [1–3]. A new IL-17-producing T cell subset, termed Th17
cells, has been described in recent years [4–7]. It has been
established that Th17 cells play critical roles in several animal
models of autoimmunity, such as experimental allergic encepha-
lomyelitis (EAE) [8] and murine arthritis models [9,10]. Besides,
Th17 cells are considered to be involved in many human
inflammatory diseases, including multiple sclerosis, psoriasis and
inflammatory arthritis [11–15]. As to AS and RA, increased Th17
cells were found in PBMC from patients with AS and RA [16]. IL-
17, secreted mainly by Th17 cells, is a cytokine shown to stimulate
RA synovial fibroblast (RASF) to release several mediators of joint
inflammation including IL-6, IL-8, GM-CSF and PGE2 [17–19].
Moreover, elevated serum levels of IL-17 and IL-23 has been
reported in AS which is one of the forms of arthritis [20].
IL-22, a member of IL-10 cytokine family, exerts its effects via a
heterodimeric transmembrane receptor complex consisting of IL-
10R2 and IL-22R1 [21]. IL-22 has been believed as an important
player in regulating inflammatory responses associated with many
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e31000inflammatory diseases. Higher expression of IL-22 mRNA was
observed in psoriatic skin lesion, and elevated serum IL-22 levels
were found in patients with psoriasis [22]. In addition, the
involvement of IL-22 in other inflammatory diseases such as
inflammatory bowel disease [23] also proves its proinflammatory
roles. However, diminishing intestinal inflammatory in a mouse
model of ulcerative colitis and providing protection to hepatocytes
during acute liver inflammation by IL-22 demonstrate its anti-
inflammatory properties [24]. The situation of IL-22 was not
completely consistent in autoimmune diseases. Consistent with
psoriasis,increasedIL-22hasalsobeenfoundinserumsamplesfrom
RA and Crohn disease patients. On the contrary, decreased plasma
IL-22 levels were found in patients with SLE [25]. So, diverse
pathogenicmechanismsandtissuemicroenvironmentsmayresultin
different contributions of IL-22 in autoimmune disease develop-
ment. The precise pathophysiologic function of IL-22 remains
unclear, and the involvement of IL-22 in AS and RA remains to be
established.
Th22 subset is a more recently identified new human T helper
subset, which is characterized by abundant secretion of IL-22 but
not IL-17 or IFN-c [26–28]. Th22 cells express the chemokine
receptors CCR4, CCR6 and CCR10 [26]. Moreover, this newly
identified CD4
+ T cells clones have low or undetectable expression
of Th1 and Th17 transcription factor T-bet and RORct, and
arylhydrocarbon receptor (AHR) has been considered to be the
key transcription factor of Th22 subset [26]. In addition, naı ¨ve T
cells differentiate toward the Th22 phneotype in the presence of
IL-6 and TNF-a[26]. All of above provide strong evidence that
Th22 cells represent an independent and terminally differentiated
T cells subtype. It has been reported that Th22 cells were detected
in psoriatic skin lesions. Moreover, the increasing circulating Th22
cells [29] suggest that Th22 cells may be implicated in the
pathogenesis of psoriasis which is a chronic inammatory disease.
In addition, elevated Th22 cells in peripheral blood of RA patients
have also been reported in our previous study. Thus, the
involvement of Th22 cells in other chronic inammatory diseases
needs to be further investigated.
The roles of both Th22 cells and IL-22 in the pathogenesis of
ankylosing spondylitis and rheumatoid arthritis are still unclear
and remain to be clarified. Therefore, to investigate their roles in
the pathogenesis of AS and RA, we examined the frequencies of
Th22 cells in peripheral blood as well as the levels of plasma IL-22
of both AS and RA patients, and assayed their correlations with
disease activity in this study.
Materials and Methods
Ethics Statement
Enrollment took place between May, 2010 and April, 2011 in
two centers: Qilu Hospital, Shandong University and Shandong
Provincial Hospital, Shandong University, China. Our research
has been approved by both the Medical Ethical Committee of
Qilu Hospital, Shandong University and the Medical Ethical
Committee of Shandong Provincial Hospital, Shandong Univer-
sity. A written informed consent document has been obtained
from each participant.
Patients and Controls
A total of 32 patients with AS according to the modified New
York criteria [30] ere recruited in this study. The Bath Ankylosing
Spondylitis Disease Activity Index (BASDAI) score [31] were
measured for the patients with AS. All patients were HLA-B27-
positive. This group consisted of 27 men and 5 women, with mean
6 SD disease duration of 8.665.9 years. The mean age of the
patients was 36.6610.2 years. A total of 20 patients with active RA
according to the criteria of the American College of Rheumatol-
ogy were included in this study [32]. The DAS28 score [33] were
measured for the patients with RA. This group consisted of 16
women and 4 men, with mean 6 SD disease duration of 8.963.9
years. The mean age of the patients was 47.569.2 years. The
demographic and key clinical information of AS and RA patients
are summarized in Table 1 and Table 2. All of the patients did not
receive immunosuppressive or immunomodulatory drugs for at
least 2 months when sampling. The major previous treatment of
AS and RA patients were shown in Table S1 and Table S2. Ten
osteoarthritis (OA) patients (3 females and 7 males; mean age
48.9610.3 years) as disease controls and twenty healthy controls (5
females and 15 males; mean age 37.969.1 years) were also
recruited in the study, and all of them did not have any
rheumatologic conditions.
Flow Cytometric Analysis
Intracellularcytokineswerestudiedbyflowcytometrytoreflexthe
cytokine-producing cells. Briefly, heparinized peripheral whole
blood (400 ml) with an equal volume of Roswell Park Memorial
Institute1640mediumwereincubatedfor4hat37uC,5%CO2inthe
presenceof25 ng/mLofphorbolmyristateacetate(PMA),1 mg/mL
of ionomycin, and 1.7 mg/ml Golgiplug(Monensin; all from Alexis
Biochemicals, San Diego, CA, USA). PMA and ionomycin are
pharmacological T-cell-activating agents that mimic signals gener-
atedbytheT-cellreceptor(TCR)complexandhavetheadvantageof
stimulating T cells of any antigen specificity. Monensin was used to
block intracellular transport mechanisms, thereby leading to an
accumulationofcytokinesinthecells.Afterincubation,thecellswere
stained with PE-Cy5-conjugated anti-CD4 monoclonal antibodies
(clone: RPA-T4, Cat: 45-0049-42) at room temperature in the dark
for 20 min. The cells were next stained with FITC-conjugated anti-
interferon (IFN)-c monoclonal antibodies (clone: 4S-BS, Cat: 11-
7319-82),PE-conjugatedanti-IL-17Amonoclonalantibodies(clone:
eBio64DEC17, Cat: 12-7179-42) and APC-conjugated anti-IL22
monoclonal antibodies (clone: 22URTI, Cat: 50-7229-42) after
fixation and permeabilization. All the antibodies were from
eBioscience, San Diego, CA, USA. Isotype controls were given to
enable correct compensation and confirm antibody specificity.
Stained cells were analyzed by flow cytometric analysis using a
FACScan cytometer equipped with CellQuest software (BD
Bioscience PharMingen). Th22, Th17, Th1 and Th1/Th17 cells
Table 1. Characteristics of the patients with Ankylosing
Spondylitis.*
Characteristics value
Age(y) 36.6610.2
Sex(male/female) 27/5
Disease duration(y) 8.665.9
ESR(mm/h) 38.2620.8
ESR(mm/h) of Healthy Control 9.564.2
CRP(mg/L) 24.9613.7
CRP(mg/L) of Healthy Control 3.461.6
BASDAI score 3.261.7
HLA-B27,positive member 32
*BASDAI=Bath Ankylosing Spondylitis Disease Activity Index (range 0–10); ESR
=erythrocyte sedimentation rate; CRP=C-reactive protein.
doi:10.1371/journal.pone.0031000.t001
Th22 and Th17 in AS and RA
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+IFNc
–IL17
–IL-22
+, CD4
+IFNc
–IL17
+,
CD4
+IFNc
+and CD4
+IFNc
+IL17
+T cellsrespectively.
IL-22 and IL-17 Enzyme-linked Immunosorbent Assay
(ELISA)
Peripheral blood was collected into heparin-anticoagulant
vacetainer tubes. Plasma was obtained from all subjects by
centrifugation and stored at –80uC for determination of cytokines.
Plasma IL-22 (Cat: BMS2047) and IL-17 (Cat: BMS2017) levels
were determined with a quantitative sandwich enzyme immuno-
assay technique in accordance with the manufacturer’s recom-
mendations (lower detection limit 9 pg/ml; eBioscience).
Clinical Assessment
BASDAI score of AS patients and disease activity score in 28-
joints (DAS28) of RA patients was calculated in our study. At the
time of clinical assessment for disease activity, blood samples were
collected for the measurement of levels of C-reactive protein
(CRP) and ESR.
Statistical Analysis
Results were expressed as mean 6 SD or median (range).
Statistical significance of Th22, Th17, Th1 and plasma IL-22 as
well as IL-17 among patients with AS, RA, OA and HC was
determined by ANOVA, and difference between two groups was
determined by Newman–Keuls multiple comparison test (q test)
unless the data were not normally distributed, in which case
Kruskal - Wallis test (H test) and Nemenyi test were used. The
Pearson or Spearman correlation test was used for correlation
analysis depending on data distribution. All tests were performed
by SPSS 17.0 system. P value less than 0.05 was considered
statistically significant.
Results
Elevated Th22 Cells Correlated with Increased Plasma
Levels of IL-22 in AS and RA Patients
We analyzed the frequency of Th22 cells based on cytokine
patterns after in vitro activation by PMA/ionomycin in short-term
cultures. The expression of a typical dot-plot of Th22 cells in
representative AS, RA as well as OA patients and healthy controls
wasshowninFig.1a.ThepercentageofTh22cellswassignificantly
elevated in AS (1.2760.42%) and RA (1.3760.49%) patients
compared to OA patients (0.7060.19%) or healthy controls
(0.6860.18%) (Fig. 1b).
In addition, we also quantified the number of Th22 cells per
volume (50mL) of peripheral blood. The number of Th22 cells was
significantly increased in AS (204634) and RA (211643) patients
compared with healthy controls (123623) after stimulation with
phorbol myristate acetate, ionomycin, and monensin for 4 h (Fig.
S2a).
Plasma levels of IL-22 were examined by ELISA. The levels of
IL-22 were significantly increased in AS (41.03616.00pg/ml) and
RA (44.53629.84pg/ml) patients compared to OA patients
(24.5363.45pg/ml) and healthy controls (25.3363.75pg/ml)
(Fig. 2a).
A positive correlation was found between Th22 cells and plasma
levels of IL-22 in AS (r=0.743, P,0.001; Fig. 3a) and RA
(r=0.548, P=0.027; Fig. 3b) patients. Moreover, positive
correlations were also found between IL-22 plasma levels and
Th17 cells (r=0.587, P=0.045; Fig. 3c) in AS patients. However,
no corresponding correlation was found in RA patients (P=0.801)
(Fig. S1l).
Elevated Th17 Cells in AS and RA Patients
The expression of a typical dot-plot of Th17 cells in
representative AS, RA, OA patients and healthy controls was
shown in Fig. 4a. We found significantly increased percentage of
Th17 cells in AS (2.5860.86%) and RA (2.5760.72%) patients
compared with OA patients (1.1560.31%) and healthy controls
(1.0760.26%)(Fig. 4b). Consistently, the number of Th17 cells per
volume (50mL) of peripheral blood was significantly increased in
AS (320636) and RA (337639) patients compared with healthy
controls (214626) after stimulation with phorbol myristate acetate,
ionomycin, and monensin for 4 h (Fig. S2b). However, there was
no significant difference regarding plasma IL-17 between each
group. (AS: 16.2864.25, P.0.05; RA: 15.0264.60, P.0.05; OA:
14.8062.88, P.0.05; HC: 14.3962.72, P.0.05) (Fig. 2b).
As to Th1 cells, there was no significant difference between each
group. (AS: 11.0563.41%, P.0.05; RA: 11.1364.09%, P.0.05;
OA:10.7362.50%,P.0.05;HC:10.3762.00,P.0.05)(Fig.1a,b).
Increased Expression of IL-17 and IL-22 Double-Positive
CD4 T Cells as well as IL-17 and IFN-c Double-Positive
CD4 T Cells in AS and RA Patients
For these experiments, we also examined the frequencies of
CD4
+IFNc
-IL17
+IL-22
+ T cells and CD4
+IFNc
+IL17
+ T cells.
Though most Th17 cells did not simultaneously express both IL-
22 and IL-17, the percentage of CD4
+IFNc
-IL17
+IL-22
+
T cells was significantly increased in AS (0.6360.34%)) and
RA (0.6560.29%) patients compared with OA patients
(0.2060.04%) and healthy controls (0.1960.05%)(Fig. 1b). In
addition, ratios of Th1/Th17 cells were significantly increased in
AS patients (0.6360.35%) and RA patients (0.6660.21%)
compared to OA patients (0.2260.07%) and healthy controls
(0.2260.06%). (Fig. 4b).
Correlation between Th22, Th17 and Th1 Cells in AS and
RA Patients
In AS patients, there was a significant positive correlation
between Th22 cells and Th17 cells (r=0.676, P,0.001) (Fig. 5a).
Similarly, a positive correlation was also found between Th22 cells
and Th17 cells (r=0.46, P=0.041) in RA patients (Fig. 5b).
However, Th1 cells failed to show a significant correlation with
Th22 cells and Th17 cells.
Table 2. Demographic and clinical characteristics of RA
patients.*
Characteristics value
No. of patients 20
Age(y) 47.569.2
Sex(male/female) 4/16
Disease duration(y) 8.963.9
RF 14/20(70%)
ESR(mm/h) 35.8627.9
CRP(mg/L) 27.1623.3
No. of swollen joints 7.363.7
No. of tender joints 8.163.8
DAS28 5.261.4
*RF=rheumatoid factor; ESR=erythrocyte sedimentation rate; CRP=C-reactive
protein; DAS28=Disease Activity Score in 28 joints.
doi:10.1371/journal.pone.0031000.t002
Th22 and Th17 in AS and RA
PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e31000The Correlation of the Frequencies of Th22 Cells and
Th17 Cells with Disease Activity or Laboratory Parameters
in AS and RA Patients
In patients with RA, there were positive correlations between
the percentage of Th22 cells and CRP level or DAS28 (r=0.576,
P =0.008 or r=0.544, P =0.013 respectively) (Fig. 6 a, b).
Consistently, positive correlations were also found between the
percentage of Th17 cells (r=0.709, P,0.001 or r =0.706,
P,0.001 respectively) (Fig. 6 c, d) and CRP level as well as
DAS28. However, the percentage of Th1 cells was not correlated
with either CRP level or DAS28 (P =0.105 or P =0.205), and
plasma level of IL-22 or IL-17 failed to show a statistical
correlation with CRP level or DAS28 (P=0.622 and P =0.357
or P=0.317 and P=0.872) in RA patients (Fig. S1j, k). In patients
with AS, there was no correlation between the percentage of Th22
cells and clinical parameters, including ESR (P=0.964), CRP
(P=0.393) and BASDAI score (P=0.226) (Fig. S1a, b, c).
Consistently, no correlation was found between plasma level of
IL-22 and clinical parameters in AS patients, including ESR
(P=0.918), CRP (P=0.862) and BASDAI score (P=0.320) (Fig.
S1g, h, i). Correlation analysis between the percentage of Th17
cells and clinical parameters also showed no association (P=0.189,
P=0.852 and P=0.733 respectively) (Fig. S1d, e, f).
Discussion
Th22 cells, a recently defined lineage of T cells distinct from
Th1, Th2 and Th17 cells, have been believed to play a
complicated and important role in inflammatory and autoimmune
diseases. The function of Th22 cells is achieved through the
signature cytokine they secreted. Th17 cells have already been
Figure 1. Circulating Th22 cells and CD4
+IFNc
-IL17
+IL-22
+ T cells are significantly increased in ankylosing spondylitis (AS) patients
and rheumatoid arthritis (RA) patients compared with osteoarthritis (OA) patients and healthy controls. a, Representative flow
cytometry dot plots example of each group. b, The percentages of circulating Th22 cells (left panel), Th1 cells (middle panel) and CD4
+IFNc
-IL17
+IL-
22
+ T cells (right panel) from AS, RA, OA patients and healthy controls after stimulation with phorbol myristate acetate, ionomycin, and monensin for
4h .( *=P,0.05).
doi:10.1371/journal.pone.0031000.g001
Th22 and Th17 in AS and RA
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including rheumatoid arthritis. However, the potential role of
Th22 cells in inflammatory arthritis such as AS and RA is far from
clear.
To determine whether Th22 is involved in AS and RA, the
percentages of Th22 cells were examined in the peripheral blood
of patients with AS, RA OA, and healthy controls in this study.
This is the first study that evaluates the relative abundance of
Th22 cells in peripheral blood of RA and AS patients. Our results
demonstrated that the percentages of Th22 cells were significantly
elevated in the peripheral blood of patients with AS and also in
those with RA compared with OA patients and healthy controls,
which was consistent with our previous experiments on RA [34].
Moreover, we also quantified the number of Th22 cells in per
volume blood. Consistent with the results of the percentage, the
number of Th22 cells in per volume of blood was significantly
increased in AS and RA patients compared to healthy controls.
Likewise, increased Th22 cells has been observed in peripheral
blood of patients with psoriasis [29], which implicating the
involvement of Th22 cells in the chronic inflammatory skin
disorder. These observations are compatible with the idea that
Th22 cells may contribute to the pathogenesis of both RA and AS,
which are two types of inflammatory arthritis. In the present study,
correlation was also found between levels of Th22 cells and disease
activity as assessed by DAS28 or the CRP concentration in RA.
However, such correlation was not observed in AS. The possible
explanation for this inconsistency between AS and RA is that
many patients with AS do not have elevated CRP or ESR levels,
so it is more difficult to assess disease activity in AS. It is known
that Th17 cells are enriched in the joints of RA patients and co-
express the chemokine receptor CCR6 and CCR4 [35]. Besides,
CCL20 [36] as well as CCL22 [37], the ligand of CCR6 and
CCR4 respectively, have already been observed in synovial fluid of
Figure 2. Concentrations of IL-22 and IL-17 in plasma of non-stimulated peripheral blood from AS, RA, OA patients and healthy
controls. a, Concentrations of IL-22 in plasma from AS, RA, OA patients and healthy controls. The levels of IL-22 was significantly increased in AS and
RA patients compared with OA patients or healthy controls. b, Concentrations of IL-17 in plasma from AS, RA, OA patients and healthy controls. As to
IL-17, there was no significant difference between AS or RA patients and OA as well as healthy controls (*= P,0.05).
doi:10.1371/journal.pone.0031000.g002
Figure 3. Correlation between the percentages of each T cell
subset and the plasma IL-22 concentrations in AS or RA
patients. a and b, Positive correlation was found between Th22 cells
and IL-22 in AS (a) and RA (b) patients. c, Positive correlation was found
between Th17 cells and IL-22 in AS patients.
doi:10.1371/journal.pone.0031000.g003
Th22 and Th17 in AS and RA
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receptor and ligand may play an important role in attracting Th17
cells to the joints in RA. Similar to Th17 cells, Th22 cells also co-
express the chemokine receptor CCR6 and CCR4. So, we can
reasonable believe that Th22 cells might selectively migrate to the
joints from peripheral blood in the similar way. Moreover, we also
speculated that Th22 cells might be elevated in the joints of RA
and AS patients, which could play a pathogenic role in the lesions.
Otherwise, what the pathogenic role does the Th22 cells play in
AS and RA when migrating to the lesion remain to be elucidated.
Then, we would focus our further investigation on the involvement
of this new subset in synovial fluid of patients’ joints.
IL-22, a cytokine of IL-10 family, is the most important
functional cytokine of Th22 cells. Considerable evidence suggests
that IL-22 may be involved in the pathogenesis of many
inflammatory diseases, but its pathophysiologic function is not
well known. To investigate the potential role of IL-22 in AS and
RA patients, we examined the concentrations of plasma IL-22 in
our experiments. In line with our previous study, elevated levels of
plasma IL-22 were also detected in AS and RA patients in the
present study, implicating that IL-22 may be involved in the
pathogenesis of both AS and RA. IL-22 has been demonstrated to
exert its biological effects via binding to the heterodimeric receptor
complex, including IL-22R1 and IL-10R2, and IL-22 activates
Jak1 and Tyk2, which further activates STAT-1, STAT-3 and
STAT-5 [38]. It has already been reported that IL-22R1 mRNA
was expressed in RA synovial tissue. In addition, activation of
ERK-1/2 as wells as p38 MAPK by IL-22 has also been reported
in RA [39]. In vitro, recombinant IL-22 promoted proliferation of
synovial fibroblasts of RA patients (RASF) and increased
production of monocyte chemoattractant protein 1 (MCP-1) by
RASF. Thus, we speculated the similar effect of IL-22 in AS
patients as in RA patients. More recently, IL-22 serum levels were
demonstrated to be associated with radiographic progression in
rheumatoid arthritis [40], which further improved the importance
of IL-22 in chronic inflammatory arthritis. In our study, plasma
IL-22 levels correlated positively with Th22 cells in both AS
patients and RA patients. In addition, correlation between plasma
IL-22 level and Th17 cells were observed in AS patients. By
contrast, no association of plasma IL-22 levels with Th17 cells was
found in RA patients. Th22 cells, Th17 cells and Th1 cells are the
main T cells subsets secreting IL22 [41,26,28,42]. The correlation
between Th17 cells and IL-22 in AS supported the idea that Th17
subset was an important T cells subset secreting IL-22 in
Figure 4. Circulating Th17 cells and Th17/Th1 cells are significantly increased in ankylosing spondylitis (AS) patients and
rheumatoid arthritis (RA) patients compared with osteoarthritis (OA) patients and healthy controls. a, Representative flow cytometry
dot plots example of each group. b, The percentages of circulating Th17 cells (left panel) and Th17/Th1 cells (right panel) from AS, RA, OA patients
and healthy controls after stimulation with phorbol myristate acetate, ionomycin, and monensin for 4 h (*= P,0.05).
doi:10.1371/journal.pone.0031000.g004
Figure 5. Correlation between the percentages of Th22 cells and the percentages of Th17 cells in AS and RA patients. a, Positive
correlation was found between Th22 cells and Th17 cells in AS patients. b, Positive correlation was found between Th22 cells and Th17 cells in RA
patients.
doi:10.1371/journal.pone.0031000.g005
Th22 and Th17 in AS and RA
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patients suggested that Th22 cells may produced much greater
portion of total IL-22, and Th17 cells may produced a relatively
smaller portion of total IL-22 in peripheral blood of RA patients
than AS patients. So far, the pathophysiologic role of IL-22 in both
AS and RA is not fully understood and need further investigation.
Considerable evidence suggests Th17 cells and Th1 cells have
been involved in the development of autoimmune diseases [43,44].
Thus, we examined the frequencies of Th17 cells and Th1 cells in
each group in this experiment. In consistence with the experiment
of Hui et al [16], the percentages of Th17 cells were demonstrated
to be significantly increased in the peripheral blood of patients
with AS and RA. Consistent with the results of Th22 cells, the
number of Th17 cells in per volume of blood was significantly
increased in AS and RA patients compared to healthy controls. In
contrast to the results for Th17 and Th22 cell, no statistical
difference was detected in percentages of Th1 cells between each
group. Our observations supported the idea that Th17 cells
contributed to the pathogenesis of AS and RA. Furthermore, we
also examined the correlation between disease activity of AS or
RA and the percentages Th17 cells. Like Th22 cells, there was a
positive correlation between disease activity and Th17 in RA
patients but not in AS patients. This inconsistent results between T
cells and disease activity in AS is unclear, and needs further study.
In this study, a positive correlation was found between the
frequencies Th22 cells and Th17 cells in peripheral blood of
patients with both AS and RA. This co-elevated level of Th22 cells
and Th17 cells suggests these two T cell subsets may play a
synergistic role in AS and RA, and the specific links between Th22
cells and Th17 cells need further investigation.
IL-17, the main cytokine of Th17 cells, contributes to the
pathogenesis of arthritis as has been demonstrated in many
experimental arthritis models. Although elevated levels of IL-17
have been observed in synovial fluid of RA patients, the levels of
this T cell cytokine in plasma of these patients is hard to detect.
Furthermore, the reports on IL-17 levels in plasma of RA or AS
patients are inconsistent [35,20]. The levels of IL-17 in plasma of
each group were also measured in this experiment. In line with
recent report [35], plasma IL-17 levels were not significantly
different between the patients and healthy controls in our study.
Moreover, the situation of IL-17 in autoimmune diseases is
different. Increased levels of IL-17 have been shown in the serum
of systemic sclerosis patients, but not in that of SLE patients or
healthy controls.
In humans, it is not unusual to encounter dual +Th1/Th17
cells. It has previously been demonstrated that T cells from
synovial fluid of RA can co-express IL-17 and IFN-c [45], and
both IL-17 and IFN-c can be secreted by T cells derived from the
joints [46]. In addition, IL-17 and IFN-c cytokines have been
shown to be co-expressed in human memory CD4+CD45+RO+ T
Figure 6. Correlation between the percentages of Th22 cells as well as Th17 cells and CRP levels as well as DAS28.
doi:10.1371/journal.pone.0031000.g006
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the percentages of Th17/Th1 cells. Consistent with a recent report
in psoriasis [29], Th17/Th1 cells were increased in peripheral
blood of AS and RA compared with OA and healthy controls.
However, cells secreting IFN-c alone were much more than those
secreting IL-17 after stimulating with PMA and ionomycin;
therefore, the contribution by Th17 cells to total IFN-c secretion
would be very low. Because Th17 cells also produced IL-22, Th17
cells that were positive for IL-22 were examined in this study. It
has been shown that IL-22-positive Th17 cells were only observed
in human but not in mouse [48]. In this experiment, increasing
percentages of CD4+IL-22+IL-17+IFNc- T cells were detected in
peripheral blood from AS and RA patients compared to OA
patients and healthy controls. Our results were in line with the
study of Colin et al [47], which demonstrated increased
percentages of IL-17+ and IL-22+CD4+ T cells in PBMCs from
treatment-naı ¨ve patients with early RA. IL-22 production by Th17
cells has been demonstrated to be dependent on IL-23 [49], and
elevated serum IL-23 level was detected in the patients with
AS [20]. Our data suggest that the tendency to develop both
CD4+IL-22+IL-17+IFNc- T cells and Th1/Th17 cells may be a
common immunologic characteristic shown in AS and RA
patients.
In conclusion, our experiments showed that the frequencies of
Th22 cells and Th17 cells were significantly increased in AS and
RA patients compared to OA patients and healthy controls.
Plasma IL-22 levels, which correlated positively with Th22 cells,
were also demonstrated to be elevated in both AS and RA
patients. The increasing percentages of Th22 cells and Th17 cells
and the elevation of IL-22 may play important roles in the
pathogenesis of AS and RA. Thus, Th22 cells and IL-22 as well as
Th17 cells may prove to be a promising therapeutic targets for AS
and RA. Further studies are awaited to clarify the pathophysio-
logic role of Th22 in AS and RA and determine the situation of
Th22 cells in AS and RA patients’ joints.
Supporting Information
Figure S1 a, b and c, No positive correlations were found
between the percentage of Th22 cells and ESR, CRP as well as
BASDAI in AS patients. d, e and f, No positive correlations were
found between the percentage of Th17 cells and ESR, CRP as well
as BASDAI in AS patients. g, h and i, No positive correlations
were found between the levels of plasma IL-22 and ESR, CRP as
well as BASDAI in AS patients. j and k, No positive correlations
were found between the levels of plasma IL-22 and CRP as well as
DAS28 in RA patients. i, No positive correlation was found
between the levels of plasma IL-22 and the percentage of Th17
cells in RA patients.
(TIF)
Figure S2 The number of Th22 cells and Th17 cells in per
volume of peripheral blood in AS patients, RA patients and
healthy controls. a, The number of Th22 cells was significantly
increased in AS and RA patients compared with healthy controls
after stimulation with phorbol myristate acetate, ionomycin, and
monensin for 4 h. b, The number of Th17 cells was significantly
increased in AS and RA patients compared with healthy controls
after stimulation with phorbol myristate acetate, ionomycin, and
monensin for 4 h. (*=P,0.05)
(TIF)
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